Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

计划入组 24 人 · 首次发布于 2016 年 8 月 5 日

Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

计划入组 23 人 · 首次发布于 2016 年 1 月 21 日

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

计划入组 26 人 · 首次发布于 2021 年 11 月 23 日

respiratory compound

KISIMA(Boehringer Ingelheim)

nuclear receptor antagonist

BOEHRINGER INGELHEIM FRANCE

France

Boehringer Ingelheim AB

Sweden

Boehringer Ingelheim Ltd.

United Kingdom

Boehringer Ingelheim Launches 'One Medicine Platform' to Accelerate Drug Development

BioMed X and Boehringer Ingelheim Complete Groundbreaking Schizophrenia Research Project

Boehringer Ingelheim Achieves Significant Pipeline Progress in First Half of 2024